IGFBP2 and breast carcinoma: These results were further validated, using western immunoblotting, in breast cancer cell lines with perturbed expression of miR-125b (via transfection with mimics, overexpressing plasmid or LNA inhibitor) or are heterogeneous in miR-125b expression, whereby increased protein expressions of both IGFBP2 and CCL28 was observed in the conditioned media from cells with high miR-125b expression or Mi/EGFPHigh subpopulations, and the protein expression reduced when miR-125b was inhibited or in Mi/EGFPLow subpopulations (Fig. 2I, Fig. S6F).